Page 7,175«..1020..7,1747,1757,1767,177..7,1807,190..»

Researchers develop method of directing stem cells to increase bone formation and bone strength

Posted: Published on February 6th, 2012

Public release date: 5-Feb-2012 [ | E-mail | Share ] Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System A research team led by UC Davis Health System scientists has developed a novel technique to enhance bone growth by using a molecule which, when injected into the bloodstream, directs the body's stem cells to travel to the surface of bones. Once these cells are guided to the bone surface by this molecule, the stem cells differentiate into bone-forming cells and synthesize proteins to enhance bone growth. The study, which was published online today in Nature Medicine, used a mouse model of osteoporosis to demonstrate a unique treatment approach that increases bone density and prevents bone loss associated with aging and estrogen deficiency. "There are many stem cells, even in elderly people, but they do not readily migrate to bone," said Wei Yao, the principal investigator and lead author of the study. "Finding a molecule that attaches to stem cells and guides them to the targets we need is a real breakthrough." Researchers are exploring stem cells as possible treatments for a wide variety of conditions and injuries, ranging from peripheral artery disease and macular degeneration to blood … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Researchers develop method of directing stem cells to increase bone formation and bone strength

Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell …

Posted: Published on February 6th, 2012

RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients. CMX001 is a broad spectrum Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the prevention of CMV in HCT recipients. In CMX001 Study 201, a double-blind, placebo-controlled trial which enrolled 230 HCT recipients, CMX001 had a statistically significant benefit versus placebo in preventing CMV viremia and/or CMV disease 13 weeks post-transplant. Francisco Marty, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute and Brigham and Women's Hospital's Division of Infectious Disease, and a lead investigator in Chimerix's CMX001 Phase 2 CMV study, presented the data during the "Best Abstracts Plenary Session" at the 2012 BMT Tandem Meetings on February 3, 2012 in San Diego, California. "This study provides positive data supporting the antiviral activity of CMX001 at different dose levels, and a better understanding of CMX001's safety and tolerability as a prophylactic agent against CMV infection, a major cause of morbidity and mortality in bone marrow transplant recipients," said Dr. Marty.  "There is a substantial unmet medical … Continue reading →

Posted in Cell Medicine | Comments Off on Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell …

FDA Skeptical of Amgen Drug Ahead of Panel

Posted: Published on February 6th, 2012

Updated with analyst comments. THOUSAND OAKS, Calif. (TheStreet) -- Amgen's(AMGN) effort to expand the use of new drug Xgeva to prevent or delay the spread of prostate cancer to the bones of patients is being met with skepticism by U.S. regulators who question whether such a claim has merit since the drug doesn't help patients live longer and may cause more side effects. The U.S. Food and Drug Administration released its critique of Xgeva ahead of an advisory panel scheduled for Wednesday. Amgen already markets Xgeva for the treatment of bone-related side effects in patients being treated for cancer. The biotech firm wants FDA permission to expand Xgeva's label to allow the drug to be used to prevent or delay bone metastases in advanced prostate cancer patients. Amgen shares were down 1% to $68.50 in early Monday trading. Investors have generally not expected Amgen to come out a winner at Wednesday's advisory panel and sales forecasts for Xgeva in this expanded indication are modest if they're modeled at all. In a phase III study which enrolled men with advanced prostate cancer at high risk for spreading to bone, treatment with Xgeva significantly improved median bone metastasis-free survival by 4.2 months … Continue reading →

Posted in Drug Side Effects | Comments Off on FDA Skeptical of Amgen Drug Ahead of Panel

"Ashley Vargas", "Project Walk Spinal Cord Injury Recovery" – Video

Posted: Published on February 6th, 2012

06-01-2012 12:28 Spinal cord injury treatment. http://www.projectwalk.org exists to provide an improved quality of life for people with spinal cord injuries through intense exercise-based recovery programs, education, support and encouragement. See more here: "Ashley Vargas", "Project Walk Spinal Cord Injury Recovery" - Video … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on "Ashley Vargas", "Project Walk Spinal Cord Injury Recovery" – Video

Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid …

Posted: Published on February 6th, 2012

WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer.  The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification in glioma, the most common form of brain cancer. Brain cancer is the leading cause of death among children and young adults under age 20. This year, more than 200,000 people in the United States will be diagnosed with either a primary or metastatic brain tumor.  There are more than 120 different types of brain tumors, making specific diagnosis and effective treatment extremely complicated. In many cases, accessing brain tissue via biopsy carries significant risk or is not surgically feasible.  The ability to sample a brain cancer's genetic characteristics through a blood or cerebrospinal fluid sample could contribute greatly to driving advances in clinical treatment and drug development. This collaboration will bring together world-leading clinicians, researchers and industry participants to develop the potential of stable, high-quality disease-specific RNA harvested from exosomes found in blood and cerebrospinal fluid. The joint effort will … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid …

Sanofi faces uphill struggle in MS drug market

Posted: Published on February 6th, 2012

* Sanofi (Paris: FR0000120578 - news) seen as smaller player in MS * Co excited about Lemtrada prospects - CEO * Experts say wider choice of drugs is best for patients PARIS, Feb 6 (Reuters) - Sanofi SA risks falling behind in the battle for share of the fast-growing multi-billion euro multiple sclerosis (MS) market, as rivals push ahead with revolutionary treatments while doubts remain over the French drugmaker's own drug candidates. Sanofi, which has relied on blood thinners and cancer therapies to drive sales but faces increased competition from generic drug versions, is preparing to submit two MS treatments for approval this year. But it faces an uphill battle to catch Novartis AG's Gilenya and Biogen Idec Inc (NasdaqGS: BIIB - news) 's BG-12, set to dominate a market that JPMorgan analysts see growing to $14 billion in 2015 from $9.6 billion last year. "Sanofi will remain a small player compared with Biogen or Novartis, but it will still remain on the radar screen," said Beatrice Muzard, an analyst at brokerage Natixis (Euronext: KN.NX - news) . MS, which has no cure, affects 2.5 million people worldwide. It is a chronic, often disabling disease that attacks the central nervous … Continue reading →

Posted in MS Treatment | Comments Off on Sanofi faces uphill struggle in MS drug market

Stem cell Q and A

Posted: Published on February 6th, 2012

Q. What are human stem cells? A. Stem cells are the blank slates of the body that are used as the building blocks for growth, repair and replacement. As blank slates, these cells can be triggered to develop into the specific types of cells that make up tissues. There are two different kinds of stem cells, based on their development potential. One category is known as pluripotent stem cells, meaning they have the ability to develop into any type of tissue in the body. Pluripotent stem cells can be broken into two subcategories: those that are derived from human embryos, and those that are created from human skin cells, based on pioneering research conducted at McMaster University. The second category are adult, or somatic, stem cells, which are found in the various organs and tissues of the body. These, too, are blank slates that can be triggered to differentiate, but they can only be transformed into the cell types that are specific to that particular tissue. “When you talk about adult stem cells, they come in different flavours and they’re very specific in their role but they don’t have the broad potential that pluripotent stem cells have,” said Dr. Mick … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cell Q and A

$30 million donation from Boris family will help McMaster turn stem cell research into therapy

Posted: Published on February 6th, 2012

McMaster University is on its way to moving stem cell research “from the bench to the bedside” thanks to a $30 million boost from a local family. The Marta and Owen Boris Foundation made the large donation to establish a human stem cell therapy centre and a unique clinic for patients with complex health conditions. Owen, the founder of Mountain Cablevision, was in talks with McMaster about investing in their work before he died last April. His children and wife contacted the university a month later and carried out his vision, firming up their commitment last November. The Boris Family Centre in Human Stem Cell Therapies will be developed as part of the McMaster Stem Cell and Cancer Research Institute using $24 million of the funds. “It’s getting over that chasm from the bench to the bedside that this (donation) is going to allow us to do,” the institute’s scientific director Dr. Mick Bhatia said. The centre will give scientists the resources to focus on converting McMaster’s breakthroughs — such as the ability to make blood or types of neural cells with stem cells — into clinical applications through investigative trials, Bhatia said. “In the absence of this donation, I … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on $30 million donation from Boris family will help McMaster turn stem cell research into therapy

Biotech: Regenerative Medicine – Hong Kong Science Park – Video

Posted: Published on February 6th, 2012

27-01-2012 00:55 Introduction to Regenerative Medicine related companies in Hong Kong Science Park Original post: Biotech: Regenerative Medicine - Hong Kong Science Park - Video … Continue reading →

Posted in Cell Medicine | Comments Off on Biotech: Regenerative Medicine – Hong Kong Science Park – Video

Parents' lawsuit claims pharmacy sickened Gig Harbor boy

Posted: Published on February 6th, 2012

A Pierce County sheriff’s deputy and his wife are suing a Gig Harbor pharmacy, claiming it twice gave their son incorrect dosages of medicine that made him very sick. Darrell Cochran, attorney for Eric and Laura Carlson, filed the lawsuit in Pierce County Superior Court earlier this week. The suit names Olympic Pharmacy and Healthcare Services as the sole defendant. The Carlsons seek unspecified damages. Jeff Bond, owner of Olympic Pharmacy, referred calls to his insurance carrier in Iowa. A representative there declined to comment. The lawsuit contends Olympic Pharmacy is “an imminent public health danger” because it has not instituted procedures to prevent similar problems. “Plaintiffs hope to help prevent future injuries to their friends and neighbors who rely on this pharmacy and to recover fair and just compensation for their injuries,” the suit states. The Carlsons contend Olympic Pharmacy in 2009 and 2011 improperly filled their son’s seizure medication, giving him too much of the medication both times. The first time the pharmacy loaded eight doses of a drug called Lorazepam in a single syringe instead of single doses in eight syringes, the suit states. The boy lapsed into unconsciousness and was hospitalized with hallucinations. Laura Carlson later … Continue reading →

Posted in Pharmacy | Comments Off on Parents' lawsuit claims pharmacy sickened Gig Harbor boy

Page 7,175«..1020..7,1747,1757,1767,177..7,1807,190..»